Company Overview and News

Global and China Automotive Steering System Industry Report 2017 - Research and Markets

2017-06-19 prnewswire
Research and Markets has announced the addition of the "Global and China Automotive Steering System Industry Report, 2017-2021" report to their offering.

China Automotive Systems Buyout Price Should Be Raised To At Least $7.50

2017-06-13 seekingalpha
China Automotive Systems, a major supplier of steering gear to the Chinese auto industry, received a buyout offer of $5.45/share from Chairman Hanlin Chen.

What analysts say to buy as Shenzhen-Hong Kong stock link opens

2016-12-04 themalaymailonline
A businessman walks with an umbrella in the financial area of Pudong in Shanghai, May 30, 2013. — Reuters picHONG KONG, Dec 5 — After months of anticipation, the opening day of Shenzhen’s exchange link with Hong Kong has finally arrived.

Fifth day of Hong Kong rises, as Britain votes and traders anticipate Stock Connect test run

2016-06-23 scmp
Hong Kong’s stock market extended its gain to five days in a row on Thursday, as confidence remained high that Britain would vote to remain a member of the European Union and speculation grew over the launch of Shenzhen-Hong Kong Stock Connect scheme.

Hong Kong stocks close higher, betting on UK staying in EU, while mainland stocks lower

2016-06-23 scmp
Gains fuelled by growing expectations that Britain will vote to remain a member of the EU and on renewed speculation over the launch of Shenzhen Hong Kong Stock Connect

China stocks near 2-week high as test run revealed for trading link

2016-06-22 scmp
Stocks in China and Hong Kong both closed at their highest levels in nearly two weeks on Wednesday, after news of a system test run by Hong Kong stock exchange reignited hopes of a launch soon of the much-anticipated stock trading link between Shenzhen and Hong Kong.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

23h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...